Drug Profile
CTS 21166
Alternative Names: ATG-Z1; CTS-21166; ZPQ 21166Latest Information Update: 21 Apr 2016
Price :
$50
*
At a glance
- Originator CoMentis
- Class Nootropics; Small molecules
- Mechanism of Action Amyloid precursor protein secretase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 21 Apr 2016 No recent reports on development identified - Phase-I for Alzheimer's disease in USA (IV)
- 16 Oct 2014 Astellas Pharma exercises option to terminate its collaboration agreement with CoMentis
- 25 Apr 2008 Astellas Pharma and CoMentis have entered into an exclusive collaboration agreement to develop and commercialise CTS 21166 worldwide